50 Years of Bold Research for a Better Tomorrow
BrightFocus Foundation is a premier private funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. We've invested nearly $300 million in research grants to more than 6,000 scientists worldwide, catalyzing countless scientific breakthroughs, life-enhancing treatments, and diagnostic tools.
Learn more about grants awarded in the most current fiscal year (nearly $25 million in funding for 95new awards in FY2022).
Apply for a Grant
To start a new application and upload attachments, you must use our ProposalCentral application portal to apply online. Click one of the links to proceed to the RFPs.
In celebration of its 50th anniversary, BrightFocus Foundation announces the launch of a yearlong campaign and microsite celebrating the international nonprofit’s strides in the fight against Alzheimer’s disease, macular degeneration, and glaucoma and toward greater awareness of the importance of funding brain and vision research and education.
Deteriorating Neurons Are Source of Human Brain Inflammation in Alzheimer’s Disease, BrightFocus Researchers Find
A team including two BrightFocus-funded Alzheimer’s disease researchers discovered that deteriorating neurons are a source of human brain inflammation, which could pave the way for therapeutics to prevent or treat Alzheimer’s disease.
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.
A new oral pill for geographic atrophy is being tested in an early-stage clinical trial.